Drug details

Oxlumo (lumasiran injection)

type of RNAi Agents

Oxlumo (lumasiran) is a HAO1-directed small interfering ribonucleic acid (siRNA) used to treat primary hyperoxaluria type1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.

This drug may have the following side effects:
  • abdominal pain
  • injection site reactions (redness, pain, itching, and swelling) and